Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Substance Abuse Treatment, Prevention, and Policy
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2016

Open Access 01-12-2016 | Research

Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services

Authors: Jemima A. Frimpong, Thomas D’Aunno

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2016

Login to get access

Abstract

Background

Health care organizations do not adopt best practices as often or quickly as they merit. This gap in the integration of best practices into routine practice remains a significant public health concern. The role of program managers in the adoption of best practices has seldom been investigated.

Methods

We investigated the association between characteristics of program managers and the adoption of hepatitis C virus (HCV) testing services in opioid treatment programs (OTPs). Data came from the 2005 (n = 187) and 2011 (n = 196) National Drug Abuse Treatment System Survey (NDATSS). We used multivariate regression models to examine correlates of the adoption of HCV testing. We included covariates describing program manager characteristics, such as their race/ethnicity, education, and their sources of information about developments in the field of substance use disorder treatment. We also controlled for characteristics of OTPs and the client populations they serve.

Results

Program managers were predominantly white and female. A large proportion of program managers had post-graduate education. Program managers expressed strong support for preventive services, but they reported making limited use of available sources of information about developments in the field of substance use disorder (SUD) treatment. The provision of any HCV testing (either on-site or off-site) in OTPs was positively associated with the extent to which a program manager was supportive of preventive services. Among OTPs offering any HCV testing to their clients, on-site HCV testing was more common among programs with an African American manager. It was also more common when program managers relied on a variety of information sources about developments in SUD treatment.

Conclusions

Various characteristics of program managers are associated with the adoption of HCV testing in OTPs. Promoting diversity among program managers, and increasing managers’ access to information about developments in SUD treatment, may help foster the adoption of best practices.
Literature
1.
2.
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The Increasing Burden of Mortality from Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8.CrossRefPubMed
3.
Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51(3):729–33.CrossRefPubMed
4.
Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46(12):1852–8.CrossRefPubMed
5.
Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61(3):783–9.CrossRefPubMed
6.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.CrossRefPubMed
7.
Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis--United States. Morb Mortal Wkly Rep Surveill Summ. 2005;56(3):1–24.
8.
Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141(9):715–7.CrossRefPubMed
9.
Glasner-Edwards S, Rawson R. Evidence-based practices in addiction treatment: review and recommendations for public policy. Health Policy. 2010;97(2–3):93–104.CrossRefPubMedPubMedCentral
10.
Kresina TF, Hoffman K, Lubran R, Clark HW. Integrating hepatitis services into substance abuse treatment programs: new initiatives from SAMHSA. Public Health Rep. 2007;122 Suppl 2:96–8.PubMed
11.
Miller WR, Sorensen JL, Selzer JA, Brigham GS. Disseminating evidence-based practices in substance abuse treatment: a review with suggestions. J Subst Abus Treat. 2006;31(1):25–39.CrossRef
12.
Center for Substance Abuse Prevention. Identifying and Selecting Evidence-Based Interventions Revised Guidance Document for the Strategic Prevention Framework State Incentive Grant Program. In: HHS Pub No (SMA)09-4205. Rockville: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration; 2009.
13.
14.
Frimpong JA, D’Aunno T, Jiang L. Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study. Am J Public Health. 2014;104(6):e1–8.CrossRef
15.
Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr. 2004;37(3):1367–75.CrossRefPubMed
16.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, et al. Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral
17.
Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126–33.CrossRefPubMedPubMedCentral
18.
Strauss SM, Astone-Twerell JM, Munoz-Plaza C, Des Jarlais DC, Gwadz M, Hagan H, Osborne A, Rosenblum A. Correlates of drug treatment program staff’s self efficacy to support their clients’ hepatitis C virus (HCV) related needs. Am J Drug Alcohol Abuse. 2007;33(2):245–51.CrossRefPubMed
19.
Litwin AH, Soloway I, Gourevitch MN. Integrating Services for Injection Drug Users Infected with Hepatitis C Virus with Methadone Maintenance Treatment: Challenges and Opportunities. Clin Infect Dis. 2005;40(Supplement 5):S339–45.CrossRefPubMed
20.
Kresina TF, Bruce RD, Lubran R, Clark HW. Integration of viral hepatitis services into opioid treatment programs. J Opioid Manag. 2008;4(6):369–81.PubMed
21.
Hood KB, Robertson AA, Baird-Thomas C. Implementing solutions to barriers to on-site HIV testing in substance abuse treatment: A tale of three facilities. Eval Program Plann. 2014;49:1–9.CrossRefPubMed
22.
Haynes LF, Korte JE, Holmes BE, Gooden L, Matheson T, Feaster DJ, Leff JA, Wilson L, Metsch LR, Schackman BR. HIV rapid testing in substance abuse treatment: Implementation following a clinical trial. Eval Program Plann. 2011;34(4):399–406.CrossRefPubMedPubMedCentral
23.
Birkhead GS, Klein SJ, Candelas AR, O’Connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo RA, Flanigan CA. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach. Int J Drug Policy. 2007;18(5):417–25.CrossRefPubMed
24.
Silvia C, McGuire M. Leading public sector networks: An empirical examination of integrative leadership behaviors. Leadersh Q. 2010;21(2):264–77.CrossRef
25.
D’Aunno T. The role of organization and management in substance abuse treatment: Review and roadmap. J Subst Abus Treat. 2006;31(3):221–33.CrossRef
26.
D’Aunno T, Vaughn TE. An organizational analysis of service patterns in outpatient drug abuse treatment units. J Subst Abuse. 1995;7(1):27–42.PubMed
27.
Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010;37(3):322–37.CrossRefPubMedPubMedCentral
28.
Young GJ, Charns MP, Shortell SM. Top manager and network effects on the adoption of innovative management practices: A study of TQM in a public hospital system. Strategic Manage J. 2001;22(10):935–51.CrossRef
29.
Guerrero EG. Managerial capacity and adoption of culturally competent practices in outpatient substance abuse treatment organizations. J Subst Abus Treat. 2010;39(4):329–39.CrossRef
30.
McConnell KJ, Hoffman KA, Quanbeck A, McCarty D. Management practices in substance abuse treatment programs. J Subst Abus Treat. 2009;37(1):79–89.CrossRef
31.
Garner BR. Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. J Subst Abus Treat. 2009;36(4):376–99.CrossRef
32.
McConnell KJ, Lindrooth RC, Wholey DR, Maddox TM, Bloom N. Management practices and the quality of care in cardiac units. JAMA Intern Med. 2013;173(8):684–92.CrossRefPubMed
33.
Putnam SM, Stiles WB, Jacob MC, James SA. Patient exposition and physician explanation in initial medical interviews and outcomes of clinic visits. Med Care. 1985;23(1):74–83.CrossRefPubMed
34.
Smedley BD, Stith AY, Nelson AR. Unequal Treatment:Confronting Racial and Ethnic Disparities in Health Care (with CD). Washington: The National Academies Press; 2003.
35.
Kabacoff RI. Leadership: What Has Age Got to do With It? New York: Research Release, Management Research Group; 2002.
36.
Jacobson WS, Palus CK, Bowling CJ. A Woman’s Touch? Gendered Management and Performance in State Administration. J Public Adm Res Theory. 2010;20(2):477–504.CrossRef
37.
Eagly AH, Johannesen-Schmidt MC. The leadership styles of women and men. J Soc Issues. 2001;57(4):781–97.CrossRef
38.
Burke S, Collins K. Gender differences in leadership styles and management skills. Women Manage Rev. 2001;16(5):244–57.CrossRef
39.
Wells R, Lemak CH, D’Aunno TA. Organizational survival in the outpatient substance abuse treatment sector, 1988–2000. Med Care Res Rev. 2005;62(6):697–719.CrossRefPubMed
40.
Wells R, Lemak CH, D’Aunno TA. Insights from a national survey into why substance abuse treatment units add prevention and outreach services. Subst Abuse Treat Prev Policy. 2006;1(1):21.CrossRefPubMedPubMedCentral
41.
Chuang E, Wells R, Alexander R, Green S. How outpatient substance abuse treatment unit director activities may affect provision of community outreach services. Drugs Educ Prevention Policy. 2013;20(2):149–59.CrossRef
42.
Miller D, Vries MFRKD, Toulouse J-M. Top Executive Locus of Control and Its Relationship to Strategy-Making, Structure, and Environment. Acad Manag J. 1982;25(2):237–53.CrossRef
43.
Boeker W. Strategic Change: The Influence of Managerial Characteristics and Organizational Growth. Acad Manag J. 1997;40(1):152–70.CrossRef
44.
Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008;70(5):606–11.CrossRefPubMed
45.
Santibanez SS, Garfein RS, Swartzendruber A, Purcell DW, Paxton LA, Greenberg AE. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health. 2006;83(1):86–100.CrossRefPubMedPubMedCentral
46.
Pollack HA, D’Aunno T. HIV testing and counseling in the nation’s outpatient substance abuse treatment system, 1995–2005. J Subst Abus Treat. 2010;38(4):307–16.CrossRef
47.
SAMHSA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2011. Data on Substance Abuse Treatment Facilities. BHSIS Series S-64, HHS Publication No. (SMA) 12-4730. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
48.
D’Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV Testing in the Nation’s Opioid Treatment Programs, 2005–2011: The Role of State Regulations. Health Serv Res. 2014;49(1):230–48.CrossRefPubMedPubMedCentral
49.
Adams TK. Outpatient Substance Abuse Treatment Surveys (OSATSS) sampling and weighting documentation for OSATSS-6, 2004. In: Survey Research Center, Institute for Social Research. Ann Harbor: University of Michigan; 2005.
50.
Alexander JA, Wells R, Jiang L, Pollack H. Organizational determinants of boundary spanning activity in outpatient substance abuse treatment programmes. Health Serv Manag Res. 2008;21(3):168–77.CrossRef
51.
SAMHSA. Addressing Viral Hepatitis in People With Substance Use Disorders. In: Treatment Improvement Protocol (TIP) 53, SAMHSA CSAT; 2011.
52.
SAMHSA. The TEDS Report: Injection Drug Abuse Admissions to Substance Abuse Treatment:1992 and 2009. Rockville: Center for Behavioral Health Statistics and Quality; 2011.
53.
Nunnaly J. Psychometric theory. New York: McGraw-Hill; 1978.
54.
StataCorp. Stata Statistical Software: Release 12. College Station: StataCorp LP; 2012.
55.
Astone JM, Strauss SM, Hagan H, Des Jarlais DC. Outpatient drug treatment program directors’ hepatitis C-related beliefs and their relationship to the provision of HCV services. Am J Drug Alcohol Abuse. 2004;30(4):783–97.CrossRefPubMed
56.
Gibbert WS, Keating SM, Jacobs JA, Dodson E, Baker E, Diem G, Giles W, Gillespie KN, Grabauskas V, Shatchkute A, et al. Training the workforce in evidence-based public health: an evaluation of impact among US and international practitioners. Prev Chronic Dis. 2013;10:E148.CrossRefPubMedPubMedCentral
57.
58.
Guerrero EG. Workforce diversity in outpatient substance abuse treatment: the role of leaders’ characteristics. J Subst Abus Treat. 2013;44(2):208–15.CrossRef
59.
Blum TC, Davis CD, Roman PM. Adopting evidence-based medically assisted treatments in substance abuse treatment organizations: roles of leadership socialization and funding streams. J Health Hum Serv Adm. 2014;37(1):37–75.PubMedPubMedCentral
60.
61.
Carlile PR. A pragmatic view of knowledge and boundaries: Boundary objects in new product development. Organ Sci. 2002;13(4):442–55.CrossRef
62.
Hambrick DC. Upper Echelons Theory: An Update. Acad Manag Rev. 2007;32(2):334–43.CrossRef
63.
Hansen MT. The Search-Transfer Problem: The Role of Weak Ties in Sharing Knowledge across Organization Subunits. Adm Sci Q. 1999;44(1):82–111.CrossRef
64.
Tushman ML, Scanlan TJ. Characteristics and external orientations of boundary spanning individuals. Acad Manag J. 1981;24(1):83–98.CrossRef
Metadata
Title
Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services
Authors
Jemima A. Frimpong
Thomas D’Aunno
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2016
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/s13011-016-0057-2

Other articles of this Issue 1/2016

Substance Abuse Treatment, Prevention, and Policy 1/2016 Go to the issue

Research

Policing, massive street drug testing and poly-substance use chaos in Georgia – a policy case study

Reviewer acknowledgement

Acknowledgement of manuscript reviewers 2015

Research

Access to substance use treatment among young adults who use prescription opioids non-medically

Debate

Dextromethorphan: a case study on addressing abuse of a safe and effective drug

Research

The misuse of Cyproheptadine: a non-communicable disease risk behaviour in Kinshasa population, Democratic Republic of Congo

Research

Violence narratives of Mexican women treated in mutual-aid residential centers for addiction treatment